

September 29, 2023

British Columbia Securities Commission

Dear Sirs / Mesdames:

Re: ME Therapeutics Inc. (the “Company”)

We refer to the non-offering prospectus of ME Therapeutics Holdings Inc. (“METX”) dated September 29, 2023 to be filed with the British Columbia Securities Commission to comply with Policy 2 – *Qualifications for Listing* of the Canadian Securities Exchange (the “CSE”) in order for METX to meet one of the eligibility requirements for the listing of METX’s common shares on the CSE by becoming a reporting issuer pursuant to applicable securities legislation in the Province of British Columbia.


We consent to being named and to the use, in the above-mentioned non-offering prospectus, of our report dated September 29, 2023 to the directors of the Company on the following financial statements:

Statements of financial position as at August 31, 2022, 2021, and 2020;

Statements of loss and comprehensive loss, changes in shareholders’ equity (deficiency), and cash flows for the years ended August 31, 2022, 2021, and 2020 and a summary of significant accounting policies and other explanatory information.

We report that we have read the non-offering prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the short form prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours very truly,



DAVIDSON & COMPANY LLP
Chartered Professional Accountants

